OneSource Pharma’s stock jumped 5% after the company announced a major regulatory milestone. Its Unit 2 manufacturing facility in Bengaluru has received Good Manufacturing Practices (GMP) certification from ANVISA, the Brazilian Health Regulatory Agency. The certification follows a successful regulatory inspection conducted in November 2024.
Unit 2 is OneSource’s flagship site for biologics manufacturing, including drug substances, injectable products, and Drug Device Combinations (DDCs). This facility is critical to the company’s global production network and enhances its capacity to supply high-quality pharmaceuticals worldwide.
The ANVISA GMP certification now enables OneSource to support pharmaceutical companies looking to register and commercialize their products in Brazil. This includes the supply of GLP-1-based DDCs like generic Semaglutide—widely used in diabetes and obesity treatment—pending product-specific approvals.
This regulatory achievement not only expands OneSource’s reach in the Latin American market but also strengthens its position as a trusted global CDMO (Contract Development and Manufacturing Organization) partner in the biologics space.
OneSource shares opened at ₹1,559.00, matching the day’s high before dipping to a low of ₹1,508.75. The stock has shown considerable movement, with a 52-week high of ₹1,800.00 and a low of ₹1,209.95.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
